Incretin Hormone Secretion Over the Day

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 203-220

  Ahrén, Bo ^a   Carr, Richard D ^b   Deacon, Carolyn F ^c  

^a LUND UNIVERSITY   (Sweden)

^b MSD A/S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diurnal; GLP 1; GUP; Incretin; Insulin; Islet hormones; Secretion

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL; BOOK; EATING; HUMAN; PHYSIOLOGY; SECRETION;

ANIMALS; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 78649341328     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00007-2     Document Type: Book

References (73)

1. Ahrén B. Autonomic regulation of islet hormone secretion-Implications for health and disease. Diabetologia 2000, 43:393-410.
2. Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-Diabetes control and potential adverse events. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:487-498.
3. Ahrén B., Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001, 50:1030-1038.
4. Ahrén B., Larsson H., Holst J.J. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur. J. Endocrinol. 1997, 137:127-131.
5. Ahrén B., Winzell M.S., Pacini G. The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. J. Endocrinol. 2008, 197:181-187.
6. Anini Y., Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003, 52:252-259.
7. Buchan A.M., Polak J.M., Capella C., Solcia E., Pearse A.G. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 1978, 56:37-44.
8. Carr R.D., Larsen M.O., Winzell M.S., Jelic K., Lindgren O., Deacon C.F., Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E779-E784.
9. Carr R.D., Larsen M.O., Jelic K., Lindgren O., Vikman J., Holst J.J., Deacon C.F., Ahrén B. Secretion and DPP-4-mediated metabolism of incretin hormones following a mixed meal or glucose ingestion in obese compared to lean, non-diabetic, men. J. Clin. Endocrinol. Metab. 2010, 95:872-878.
10. Chu Z.L., Carroll C., Alfonso J., Gutierrez V., He H., Lucman A., Pedraza M., Mondala H., Gao H., Bagnol D., Chen R., Jones R.M., et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 2008, 149:2038-2047.
11. Creutzfeldt W. The incretin concept today. Diabetologia 1979, 16:75-85.
12. D'Alessio D.A., Denney A.M., Hermiller L.M., Prigeon R.L., Martin J.M., Tharp W.G., Saylan M.L., He Y., Dunning B.E., Foley J.E., Pratley R.E. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2009, 94:81-88.
13. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regul. Pept. 2005, 128:117-124.
14. Deacon C.G., Wamberg S., Bie P., Hughes T.E., Holst J.J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. 2002, 172:355-362.
15. Dubé P.E., Brubaker P.L. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm. Metab. Res. 2004, 36:755-760.
16. Dumoulin V., Dakka T., Plaisancie P., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 1995, 136:5182-5188.
17. Edfalk S., Steneberg P., Edlund H. GPR40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
18. Eissele R., Göke R., Willemer S., Harthus H.P., Vermeer H., Arnold R., Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 1992, 22:283-291.
19. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent polypeptide secretion in response to nutrient ingestion in man. Acute post-prandial and 24-h secretion patterns. J. Endocrinol. 1993, 138:159-166.
20. Gribble F.M., Williams L., Simpson A.K., Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003, 52:1147-1154.
21. Hansen L., Hartmann B., Mineo H., Holst J.J. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul. Pept. 2004, 118:11-18.
22. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., Dietrich B., Golor G., Schrodter A., Keymeulen B., Lasseter K.C., Kipnes M.S., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2006, 91:4612-4619.
23. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
24. Højberg P.V., Zander M., Vilsbøll T., Knop F.K., Krarup T., Vølund A., Holst J.J., Madsbad S. Near-normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes mellitus. Diabetologia 2008, 51:632-640.
25. Holst J.J. The physiology of glucagon-like peptide-1. Physiol. Rev. 2007, 87:1409-1439.
26. Jang H.J., Kokrashvili Z., Theodorakis M.J., Carlson O.D., Kim B.J., Zhou J., Kim H.H., Xu X., Chan S.L., Juhaszova M., Bernier M., Mosinger B., et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15069-15074.
27. Jarrett R.J., Baker I.A., Keen H., Oakley N.W. Diurnal variation in oral glucose tolerance: Blood sugar and plasma insulin levels in morning, afternoon, and evening. Br. Med. J. 1972, 1:199-201.
28. Jones I.R., Owens D.R., Sarsons D.L., Bloom S.R. Day profiles of glucose dependent insulinotropic polypeptide (GIP) in normal subjects. Horm. Metab. Res. 1985, 17:660-662.
29. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512.
30. Knop F.K., Vilsboll T., Höjberg P.V., Larsen S., Madsbad S., Volund A., Holst J.J., Krarup T. Reduced incretin effect in T2DM: Cause or consequence of the diabetic state?. Diabetes 2007, 56:1951-1959.
31. Knop F.K., Aaboe K., Vilsboll T., Madsbad S., Holst J.J., Krarup T. Reduced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects. Diabetes 2008, 57:A410.
32. Lee A., Patrick P., Wishart J., Horowitz M., Morley J.E. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes. Metab. 2002, 4:329-335.
33. Lindgren O., Mari A., Deacon C.F., Carr R.D., Winzell M.S., Vikman J., Ahrén B. Differential islet and incretin hormone response in morning versus afternoon after standardized meal in healthy men. J. Clin. Endocrinol. Metab. 2009, 94:2887-2892.
34. Mari A., Gastaldelli A., Natali A., Ostergard T., Schmitz O., Ferrannini E. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: Modelling analysis of 24-h triple meal tests. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E541-E546.
35. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., Deacon C.F., Holst J.J., Foley J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function ion patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90:4888-4894.
36. Meier J.J., Gallwitz B., Askenas M., Vollmer K., Deacon C.F., Holst J.J., Schmidt W.E., Nauck M.A. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 2005, 48:1872-1881.
37. Miholic J., Ørskov C., Holst J.J., Kotzerke J., Meyer H.J. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci. 1991, 36:1361-1370.
38. Mortensen K., Christensen L.L., Holst J.J., Ørskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 2003, 114:189-196.
39. Muscelli E., Mari A., Natali A., Astiarraga B.D., Camastra S., Frascerra S., Holst J.J., Ferrannini E. Impact of inretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am. J. Physiol. Endocrinol. Metab. 2006, 291:1144-1150.
40. Muscelli E., Mari A., Casolaro A., Camastra S., Seghieri G., Gastaldelli A., Holst J.J., Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
41. Naslund E., Hellström P.M. Glucagon-like peptide-1 in the pathogenesis of obesity. Drugs News Persp. 1998, 11:92-97.
42. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P.O., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986, 63:492-498.
43. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
44. Nauck M.A., Heimesaat M.M., Ørskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 91:301-307.
45. Nauck M.A., Siemsgluss J., Ørskov C., Holst J.J. Release of glucagon-like peptide-1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z. Gastroenterol. 1996, 34:159-166.
46. Nauck M.A., El-Quaghlidi A., Gabrys B., Hücking K., Holst J.J., Deacon C.F., Gallwitz B., Schmidt W.E., Meier J.J. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul. Pept. 2004, 122:209-217.
47. Nyholm B., Walker M., Gravholt C.H., Shearing O.A., Sturis J., Alberti K.G., Holst J.J., Schmitz O. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic patients: Evidence of several aberrations. Diabetologia 1999, 42:1314-1323.
48. Ørskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 1996, 31:665-670.
49. Parker H.E., Habib A.M., Rogers G.J., Gribble F.M., Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009, 52:289-298.
50. Qualmann C., Nauck M.A., Holst J.J., Ørskov C., Creutzfeldt W. Glucagon-like peptide-1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose). Scand. J. Gastroenterol. 1995, 30:892-896.
51. Ranganath L.R., Beety J.M., Morgan L.M., Wright J.W., Howland R., Marks V. Attenuated GLP-1 secretion in obesity: Cause of consequence?. Gut 1996, 38:916-919.
52. Rask E., Olsson T., Söderberg S., Johnson O., Seckl J., Holst J.J., Ahrén B. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diab. Care 2001, 24:1640-1645.
53. Rask E., Olsson T., Söderberg S., Holst J.J., Tura A., Pacini G., Ahrén B. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004, 53:624-631.
54. Ross S.A., Brown J.C., Dupré J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977, 26:525-529.
55. Rozengurt N., Wu S.V., Chen M.C., Huang C., Sternini C., Rozengurt E. Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon. Am. J. Physiol. 2006, 291:G792-G802.
56. 1c levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 2006, 155:485-493.
57. Schirra J., Katschinski M., Weidmann C., Schafer T., Wank U., Arnold R., Göke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest. 1996, 97:92-103.
58. Sinha Roy R., Bergeron R., Zhu L., He H., Jiang G., Liu F., Lyons K., Pryor K., Yao J., Zhang B.B., Thornberry N. Metformin is a GLP-1 secretagogue, not a dipeptidyl peptidase-4 inhibitor. Diabetologia 2007, 50(Suppl. 1):S284.
59. Sugiyama K., Manaka H., Kato T., Yamatani K., Tominaga M., Sasaki H. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 1994, 55:24-28.
60. Sykes S., Morgan L.M., English J., Marks V. Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. J. Endocrinol. 1980, 85:201-207.
61. Toft-Nielsen M., Madsbad S., Holst J.J. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on pancreatic glucoregulatory hormones. Diabetes 1996, 45:552-556.
62. Toft-Nielsen M., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., Holst J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2001, 86:3717-3723.
63. Vaag A.A., Holst J.J., Vølund A., Beck-Nielsen H.B. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus-Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur. J. Endocrinol. 1996, 135:425-432.
64. Vahl T.P., Drazen D.L., Seeley R.J., DD́Alessio D.A., Woods S.C. Meal-anticipatory glucagon-like peptide-1 secretin in rats. Endocrinology 2010, 151:569-575.
65. Vazzquez Roque M.I., Camilleri M., Stephens D.A., Jensen M.D., Burton D.D., Baxter K.I., Zinsmeister A.R. Gastric sensorimotor functions and hormone profiles in normal weight, overweight, and obese people. Gastroenterology 2006, 131:1717-1724.
66. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
67. Vilsbøll T., Knop F.K., Krarup T., Johansen A., Madsbad S., Larsen S., Hansen T., Pedersen O., Holst J.J. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-Regardless of atiology and phenotype. J. Clin. Endocrinol. Metab. 2003, 88:4897-4903.
68. Vilsbøll T., Krarup T., Sonne J., Madsbad S., Volund A., Juul A.G., Holst J.J. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2003, 88:2706-2713.
69. Vollmer K., Holst J.J., Baller B., Ellrichmann M., Nauck M.A., Schmidt W.E., Meier J.J. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
70. Wang S.Y., Chi M.M., Li L., Moley K.H., Wice B.M. Studies with GIP/Ins cells indicate secretion by gut K cells is KATP channel independent. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E988-E1000.
71. Wisén O., Johansson C. Gastrointestinal function in obesity: Motility, secretion and absorption following a liquid test meal. Metabolism 1992, 41:390-395.
72. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Commun. 2002, 298:779-784.
73. Zimmet P.Z., Wall R.J., Rome R., Stimmler L., Jarrett R.J. Diurnal variation in glucose tolerance associated with changes in plasma insulin, growth hormone, and non-esterified fatty acids. Br. Med. J. 1974, 1:485-488.